1. A securities class action lawsuit filed against TransMedics Inc. has begun. 2. Allegations include false statements and unsafe practices by TransMedics. 3. Investors can apply as lead plaintiffs until April 15, 2025. 4. Involved parties claim high potential for scrutiny and regulatory risks. 5. Previous misconduct claims can affect stock performance negatively.
Legal actions can significantly affect stock prices, as seen with similar past cases, like those involving Theranos or Valeant, where litigation substantially decreased trust and subsequently stock value. The allegations of fraudulent practices and safety issues can lead to long-term reputational damage.
The lawsuit directly involves TMDX, indicating high risk to shareholder value and future business operations. Given previous cases, investor sentiment could be heavily swayed by ongoing developments.
Legal challenges often drag on, creating uncertainty that impacts investor confidence for years ahead. This reflects the case of Valeant Pharmaceuticals, whose issues took a prolonged period to stabilize despite many positive developments.
/PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against TransMedics Group, Inc. (“TransMedics”) (NASDAQ: TMDX) on behalf of those who purchased or otherwise acquired TransMedics securities between February 28, 2023, and January 10, 2025, inclusive (the “Class Period”). The lead plaintiff deadline is April 15, 2025.
If you suffered TransMedics losses, you may CLICK HERE or copy and paste the following link into your browser: https://www.ktmc.com/new-cases/transmedics-group-inc?utm_source=PR&utm_medium=link&utm_campaign=tmdx&mktm=r
You can also contact attorney Jonathan Naji, Esq. by calling (484) 270-1453 or by email at [email protected].
The complaint alleges that, throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (1) TransMedics used kickbacks, fraudulent overbilling, and coercive tactics to generate business and revenue; (2) TransMedics engaged in unsafe practices and hid safety issues and generally lacked safety oversight; and (3) the foregoing subjected TransMedics to heightened risk of scrutiny and regulatory risk.
TransMedics investors may, no later than April 15, 2025, seek to be appointed as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, LLP or other counsel, or may choose to do nothing and remain an absent class member. A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. The lead plaintiff is usually the investor or small group of investors who have the largest financial interest and who are also adequate and typical of the proposed class of investors. The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff.
Kessler Topaz Meltzer & Check, LLP encourages TransMedics investors who have suffered significant losses to contact the firm directly to acquire more information.
CLICK HERE TO SIGN UP FOR THE CASE OR GO TO: https://www.ktmc.com/new-cases/transmedics-group-inc?utm_source=PR&utm_medium=link&utm_campaign=tmdx&mktm=r
Kessler Topaz Meltzer & Check, LLP prosecutes class actions in state and federal courts throughout the country and around the world. The firm has developed a global reputation for excellence and has recovered billions of dollars for victims of fraud and other corporate misconduct. All of our work is driven by a common goal: to protect investors, consumers, employees and others from fraud, abuse, misconduct and negligence by businesses and fiduciaries. The complaint in this action was not filed by Kessler Topaz Meltzer & Check, LLP. For more information about Kessler Topaz Meltzer & Check, LLP please visit www.ktmc.com.
Kessler Topaz Meltzer & Check, LLP
Jonathan Naji, Esq.
(484) 270-1453
280 King of Prussia Road
Radnor, PA 19087
[email protected]
May be considered attorney advertising in certain jurisdictions. Past results do not guarantee future outcomes.
SOURCE Kessler Topaz Meltzer & Check, LLP